|0.3630||-0.0219||-5.69%||Vol 218.60K||1Y Perf -80.76%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||0.01 2.31%|
|Target Price||6.25||Analyst Rating||— 0.00|
|Potential %||1.62K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||0.14||Earnings Rating||Neutral|
|Market Cap||6.87M||Earnings Date||13th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.34|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||270.28K|
|Avg. Monthly Volume||1.28M|
|Avg. Quarterly Volume||693.37K|
Evelo Biosciences Inc. (NASDAQ: EVLO) stock closed at 0.3849 per share at the end of the most recent trading day (a -3.77% change compared to the prior day closing price) with a volume of 158.67K shares and market capitalization of 6.87M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 98 people. Evelo Biosciences Inc. CEO is Balkrishan Gill.
The one-year performance of Evelo Biosciences Inc. stock is -80.76%, while year-to-date (YTD) performance is -76.09%. EVLO stock has a five-year performance of -96.44%. Its 52-week range is between 0.3007 and 44.2, which gives EVLO stock a 52-week price range ratio of 0.14%
Evelo Biosciences Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 16.44, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -117.99%, a ROC of -152.34% and a ROE of -564.20%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Evelo Biosciences Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.34 for the next earnings report. Evelo Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Evelo Biosciences Inc. is — (0), with a target price of $6.25, which is +1 621.76% compared to the current price. The earnings rating for Evelo Biosciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evelo Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evelo Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.21, ATR14 : 0.14, CCI20 : -41.14, Chaikin Money Flow : 0.08, MACD : -0.29, Money Flow Index : 68.77, ROC : -47.62, RSI : 31.39, STOCH (14,3) : 8.38, STOCH RSI : 0.00, UO : 46.76, Williams %R : -91.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evelo Biosciences Inc. in the last 12-months were: Bodmer Mark (Sold 0 shares of value $0 ), Bodmer Mark (Sold 100 602 shares of value $15 307 ), Duncan Mchale (Sold 0 shares of value $0 ), Duncan Mchale (Sold 76 687 shares of value $11 961 ), Simba Gill (Sold 0 shares of value $0 ), Simba Gill (Sold 2 510 shares of value $11 173 ), Stephen J. Carriere (Sold 0 shares of value $0 ), Stephen J. Carriere (Sold 151 shares of value $160 ), Thorell Marella (Sold 0 shares of value $0 ), Thorell Marella (Sold 7 814 shares of value $20 975 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.